Gary Globe
Overview
Explore the profile of Gary Globe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
885
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Di Tanna G, Angell B, Urbich M, Lindgren P, Gaziano T, Globe G, et al.
Pharmacoeconomics
. 2022 Aug;
40(11):1095-1105.
PMID: 35960435
Background: The rate of events such as recurrent heart failure (HF) hospitalization and death are known to dramatically increase directly after HF hospitalization. Furthermore, the number of HF hospitalizations is...
2.
McHorney C, Mansukhani S, Anatchkova M, Taylor N, Wirtz H, Abbasi S, et al.
PLoS One
. 2021 Mar;
16(3):e0248240.
PMID: 33705486
Background: Heart failure is rising in prevalence but relatively little is known about the experiences and journey of patients and their caregivers. The goal of this paper is to present...
3.
Di Tanna G, Urbich M, Wirtz H, Potrata B, Heisen M, Bennison C, et al.
Pharmacoeconomics
. 2020 Nov;
39(2):211-229.
PMID: 33251572
Background And Objectives: New treatments and interventions are in development to address clinical needs in heart failure. To support decision making on reimbursement, cost-effectiveness analyses are frequently required. A systematic...
4.
Felker G, Solomon S, McMurray J, Cleland J, Abbasi S, Malik F, et al.
Circ Heart Fail
. 2020 Nov;
13(12):e007814.
PMID: 33176437
Background: Chronic heart failure with reduced ejection fraction impairs health-related quality of life (HRQL). Omecamtiv mecarbil (OM)-a novel activator of cardiac myosin-improves left ventricular systolic function and remodeling and reduces...
5.
Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz H, et al.
Pharmacoeconomics
. 2020 Aug;
38(11):1219-1236.
PMID: 32812149
Background: Heart failure presents a growing clinical and economic burden in the USA. Robust cost data on the burden of illness are critical to inform economic evaluations of new therapeutic...
6.
Wirtz H, Sheer R, Honarpour N, Casebeer A, Simmons J, Kurtz C, et al.
J Am Heart Assoc
. 2020 Aug;
9(16):e015042.
PMID: 32805181
Background Patients hospitalized with heart failure (HF) with reduced ejection fraction have high risk of rehospitalization or death. Despite guideline recommendations based on high-quality evidence, a substantial proportion of patients...
7.
Di Tanna G, Wirtz H, Burrows K, Globe G
PLoS One
. 2020 Jul;
15(7):e0235970.
PMID: 32614921
[This corrects the article DOI: 10.1371/journal.pone.0224135.].
8.
Di Tanna G, Wirtz H, Burrows K, Globe G
PLoS One
. 2020 Jan;
15(1):e0224135.
PMID: 31940350
Background: The ability to predict risk allows healthcare providers to propose which patients might benefit most from certain therapies, and is relevant to payers' demands to justify clinical and economic...
9.
Di Tanna G, Chen S, Bychenkova A, Wirtz H, Burrows K, Globe G
Pharmacoecon Open
. 2019 Aug;
4(3):397-401.
PMID: 31452068
Various decision analytic models exist for evaluating the cost-effectiveness of pharmacological interventions for heart failure (HF). Despite this, studies that explore drivers influencing these modeling approaches remain scarce. Through a...
10.
Globe G, Wiklund I, Mattera M, Zhang H, Revicki D
J Patient Rep Outcomes
. 2019 Apr;
3(1):22.
PMID: 30945020
Background: The Asthma Symptom Diary was developed to assess severity of symptoms in patients with moderate to severe asthma, and has evidence supporting reliability and validity. Only limited information is...